Development of combination therapy against influenza pneumonia
- Summary
- This invention offers a novelcombination therapy for influenza pneumonia. The drugs used in this combinationtherapy targets both neutrophil-induced ARDS and the virus itself, providing ahost of beneficial synergistic effects. According to the invention, a novel combinationtherapy targeting the host response has been used in combination with anantiviral agent, oseltamivir, for the treatment of severe influenza infectionin mice. Based on the findings, dual-treatment significantly enhances thesurvival of mice after lethal influenza challenge, when compared to treatmentof anti-viral alone.
- Technology Benefits
- Reduced neutrophil influxDecreased vascular leakageDecreased endothelial damageDecreased release of NETsSynergistic therapeutic increases survival in mice
- Technology Application
- Therapeutictreatment for influenza pneumonia
- Detailed Technology Description
- None
- *Abstract
-
None
- *Background
- Influenza A viruses pose significantpublic health problems with frequent outbreaks worldwide, and can lead to acuterespiratory distress syndrome (ARDS), which remains the major cause of death ininfluenza pneumonia. Due to high mutation rates introduced by the viral RNApolymerase and consequent resistance to antiviral drugs, controllinginfluenza-induced morbidity and mortality is a major challenge. Althoughtype-specific immunization is effective, the likelihood the flu vaccine willprotect a person varies from year-to-year. In addition, treatment ofnon-immunized, infected patients with current antiviral agents is relativelyineffective. Because the pathology of influenza is largely mediated by the hostresponse to infection, a therapeutic approach targeting both the virus and thehost response is desirable.
- *Stage of Development
- Proof-of-concept.
- Country/Region
- USA
For more information, please click Here
